Quantum Partners invest in Neoprobe
This article was originally published in Clinica
Executive Summary
An investment by Quantum Partners, a fund advised by Soros Fund Management, has netted cancer diagnostics company Neoprobe $5.8 million. Quantum purchased 575,000 stock for $10.50 a share. This raises Quantum's stake in Neoprobe to 4.3%. The company says the proceeds will assist in the development of its RIGScan products for treatment of breast, ovarian and prostate cancers, a technology which consists of gamma-detecting instruments, cancer-targeting agents and methods for their use.
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.